There remains a need to identify patients who will derive benefits from adjunctive techniques on top of pulmonary vein ...
The observed changes were favorable, but results may have been affected by better-than-normal care in the control arm.
In the trial, 20% of patients didn’t respond well to the PCSK9 inhibitor—could genetic markers be used to tailor therapy?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback